The CIMIT Media Center

CIMIT is the Center for Integration of Medicine and Innovative Technology. A non-profit consortium of Boston-area teaching hospitals and engineering schools, CIMIT provides innovators with resources to explore, develop and implement novel technological solutions for today’s most urgent healthcare problems.

Consortium members are Beth Israel Deaconess Medical Center, Boston Medical Center, Boston University, Brigham and Women’s Hospital, Charles Stark Draper Laboratory, Children’s Hospital Boston, Harvard Medical School, Massachusetts General Hospital, Massachusetts Institute of Technology, Newton-Wellesley Hospital and Partners HealthCare.

Learn more about CIMIT.

Press Release: 12.18.08

OptiNose joins CIMIT ILP

OptiNose, a drug-delivery company focused on the nasal drug-delivery market, recently became a member of the CIMIT Industry Liaison Program. The Norwegian enterprise was founded in 2000 to commercialize a novel nasal drug delivery system that achieves targeted delivery to sites that are poorly accessed by existing nasal sprays.

OptiNose has developed innovative nasal drug delivery devices that enable nasal administration of CNS (nose to brain), systemic and topical nasal formulations and also vaccines. OptiNose’s unique breath-actuated devices deliver drug to targeted regions of the nasal cavity, including the sinuses and the olfactory region, without lung deposition, unlike traditional nasal inhalers, nasal sprays or nebulizers. The company offers both single and multi-use intranasal delivery devices for liquid and powder formulations.

Core patents have been granted in Europe and the U.S. Variants of the basic delivery system are available for powder and liquid delivery. The technology has been successfully tested in a number of clinical trials including gamma scintigraphy studies to confirm deposition, studies evaluating the immune response to conventional antigens and studies evaluating the delivery of CNS active compounds.

The company’s technology has significant market potential in several major disease areas. The OptiNose devices can deliver drug to the upper posterior segment of the nose where it can access the entrances to the sinuses to treat rhinitis and sinusitis.

CIMIT represents a significant opportunity for OptiNose to access a network of clinicians, scientists and engineers in the U.S. The CIMIT infrastructure will provide a useful springboard for clinical development and commercialization of our technology and products in the U.S., OptiNose officials said.

» More CIMIT Press Releases.

» More CIMIT In the News.